Merck Kgaa Dm 5 (MKGAF) 107.3900 $MKGAF
Forget Mylan, Buy These 3 Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 1:44PM CDT
With Mylan under pricing scrutiny, investors should focus on these top-ranked drug stocks now.
LCI: 34.23 (-0.60), ENDP: 21.03 (unch), VRX: 30.83 (-0.26), BSTC: 36.98 (+0.54), MYL: 43.03 (+0.18), TEVA: 51.55 (+0.35), USNA: 136.45 (-1.08)
Mylan (MYL) Draws Flak for Over Pricing EpiPen, Stock Down
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 6:41AM CDT
Mylan's (MYL) shares took a beating after U.S. senators raised questions about the company's massive price hike of epinephrine auto-injector, EpiPen.
ANIP: 63.17 (+0.30), MYL: 43.03 (+0.18), SNY: 38.79 (+0.34)
Intrexon (XON) Reports Wider Loss in Q2, Revenues Increase
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 4:10PM CDT
Intrexon (XON) reported a loss of 42 cents per share in second-quarter 2016, compared to the year-ago figure of 37 cents.
ZIOP: 5.26 (+0.09), ANIP: 63.17 (+0.30), XON: 26.12 (+0.44)
Merck KGaA (MKGAF) Q2 Earnings Fall, Guides Up on Sales
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:39AM CDT
Merck KGaA (MKGAF) reported second-quarter 2016 earnings of 80 cents on sales of $4.3 billion.
BMRN: 96.22 (+1.25), PFE: 34.82 (+0.05), ANIK: 48.36 (-0.36)
Merck KGaA (MKGAF) Q2 Earnings Fall But View Raised
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 3:29AM CDT
Merck KGaA (MKGAF) second-quarter 2016 earnings per American Depositary Receipt (ADR) came in at 80 cents.
What's in Store for Merck KGaA (MKGAF) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:06AM CDT
Merck KGaA (MKGAF) is scheduled to report second-quarter 2016 earnings results on Aug 4.
IPXL: 23.94 (+0.11), IRWD: 13.63 (+0.13), PFE: 34.82 (+0.05)
Merck KGaA's Q1 Earnings Increase Y/Y, Offers 2016 View
Zacks Equity Research - Zacks Investment Research - Fri May 20, 9:33AM CDT
Merck KGaA (MKGAF) reported first-quarter 2016 earnings of $1.50 on sales of $4 billion.
BMRN: 96.22 (+1.25), PFE: 34.82 (+0.05), BMY: 58.77 (+0.01)
Merck KGaA (MKGAF) Q1 Earnings Increased Y/Y
Zacks Equity Research - Zacks Investment Research - Thu May 19, 2:24AM CDT
Merck KGaA (MKGAF) first-quarter 2016 earnings per American Depositary Receipt (ADR) came in at $1.5.
Merck KGaA (MKGAF) Q1 Earnings: What Awaits the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:38AM CDT
Merck KGaA (MKGAF) is scheduled to report its first-quarter 2016 earnings results on May 19.
AXON: 16.69 (+0.61), BMRN: 96.22 (+1.25), PFE: 34.82 (+0.05)
Intrexon (XON) Q1 Loss Wider than Expected, Revenues Miss
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:30AM CDT
Intrexon Corporation (XON) reported a wider-than-expected first-quarter 2016 loss of 32 cents per share.
FCSC: 0.87 (-0.02), ANIP: 63.17 (+0.30), XON: 26.12 (+0.44)
Pfizer & Merck KGaA Partner with Syndax for Ovarian Cancer
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 12:50PM CST
Pfizer (PFE) and Merck KGaA (MKGAF) teamed up with Syndax Pharmaceuticals to evaluate the avelumab/entinostat combination for ovarian cancer.
PFE: 34.82 (+0.05), HZNP: 19.43 (+0.25), ARNA: 1.63 (unch)
Pfizer/Merck KGaA Start Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 3:30PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of ovarian cancer and urothelial cancer.
ACHN: 8.54 (-0.06), PFE: 34.82 (+0.05), ANIK: 48.36 (-0.36)
Pfizer/Merck KGaA Begin Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Thu Dec 10, 2:20PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of advanced or metastatic gastric/gastro-esophageal junction cancers.
ACHN: 8.54 (-0.06), PFE: 34.82 (+0.05), ANIK: 48.36 (-0.36)
Merck KGaA-Pfizer's Avelumab May Get Orphan Status in EU
Zacks Equity Research - Zacks Investment Research - Fri Nov 27, 1:40PM CST
Merck KGaA (MKGAF) and Pfizer (PFE) announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for immunotherapy candidate, avelumab.
MRK: 62.85 (+0.53), PFE: 34.82 (+0.05), CORT: 5.50 (+0.05)
Pfizer's (PFE) Xalkori Positive in Another Phase III Study
Arpita Dutt - Zacks Investment Research - Thu Nov 19, 1:52PM CST
Pfizer's (PFE) Xalkori scored in another phase III study. The company also got breakthrough therapy status for avelumab.
AGN: 237.93 (+1.62), PFE: 34.82 (+0.05), LLY: 78.24 (+0.23)
Intrexon (XON) Reports Wider-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Tue Nov 10, 9:30AM CST
Intrexon Corporation (XON) reported third-quarter 2015 loss of 34 cents per share.
XON: 26.12 (+0.44), BXLT: 46.02 (-0.18), ANIK: 48.36 (-0.36)
Merck KGaA/Pfizer's Avelumab Gets Fast Track Status
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:50PM CDT
Merck KGaA (MKGAF) and Pfizer announced that avelumab received fast track status from the FDA for metastatic merkel cell carcinoma.
MRK: 62.85 (+0.53), PFE: 34.82 (+0.05), CORT: 5.50 (+0.05)
Merck KGaA's Pipeline on Track, Updates Key R&D Projects
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:40PM CDT
Merck KGaA (MKGAF) provided an update regarding the stages of development of its key immuno-oncology and oncology pipeline candidates.
ENDP: 21.03 (unch), PFE: 34.82 (+0.05), CORT: 5.50 (+0.05)
BioMarin (BMRN) to Acquire Rights to Phenylketonuria Drugs
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:10PM CDT
BioMarin (BMRN) announced that it has acquired all global rights to Kuvan and pegvaliase from Merck Serono, a division of Merck KGaA (MKGAF).
BMRN: 96.22 (+1.25), NVET: 4.22 (-0.11), REGN: 402.97 (+2.72)
Roche's Primary Progressive MS Drug Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Mon Sep 28, 3:20PM CDT
Roche (RHHBY) announced encouraging results from the phase III ORATORIO study on ocrelizumab for primary progressive multiple sclerosis.
PFE: 34.82 (+0.05), LLY: 78.24 (+0.23), NVS: 79.31 (-0.24)
Forget Mylan, Buy These 3 Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 1:44PM CDT
With Mylan under pricing scrutiny, investors should focus on these top-ranked drug stocks now.
LCI: 34.23 (-0.60), ENDP: 21.03 (unch), VRX: 30.83 (-0.26), BSTC: 36.98 (+0.54), MYL: 43.03 (+0.18), TEVA: 51.55 (+0.35), USNA: 136.45 (-1.08)
Mylan (MYL) Draws Flak for Over Pricing EpiPen, Stock Down
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 6:41AM CDT
Mylan's (MYL) shares took a beating after U.S. senators raised questions about the company's massive price hike of epinephrine auto-injector, EpiPen.
ANIP: 63.17 (+0.30), MYL: 43.03 (+0.18), SNY: 38.79 (+0.34)
Intrexon (XON) Reports Wider Loss in Q2, Revenues Increase
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 4:10PM CDT
Intrexon (XON) reported a loss of 42 cents per share in second-quarter 2016, compared to the year-ago figure of 37 cents.
ZIOP: 5.26 (+0.09), ANIP: 63.17 (+0.30), XON: 26.12 (+0.44)
Merck KGaA (MKGAF) Q2 Earnings Fall, Guides Up on Sales
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:39AM CDT
Merck KGaA (MKGAF) reported second-quarter 2016 earnings of 80 cents on sales of $4.3 billion.
BMRN: 96.22 (+1.25), PFE: 34.82 (+0.05), ANIK: 48.36 (-0.36)
Merck KGaA (MKGAF) Q2 Earnings Fall But View Raised
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 3:29AM CDT
Merck KGaA (MKGAF) second-quarter 2016 earnings per American Depositary Receipt (ADR) came in at 80 cents.
What's in Store for Merck KGaA (MKGAF) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:06AM CDT
Merck KGaA (MKGAF) is scheduled to report second-quarter 2016 earnings results on Aug 4.
IPXL: 23.94 (+0.11), IRWD: 13.63 (+0.13), PFE: 34.82 (+0.05)
Merck KGaA's Q1 Earnings Increase Y/Y, Offers 2016 View
Zacks Equity Research - Zacks Investment Research - Fri May 20, 9:33AM CDT
Merck KGaA (MKGAF) reported first-quarter 2016 earnings of $1.50 on sales of $4 billion.
BMRN: 96.22 (+1.25), PFE: 34.82 (+0.05), BMY: 58.77 (+0.01)
Merck KGaA (MKGAF) Q1 Earnings Increased Y/Y
Zacks Equity Research - Zacks Investment Research - Thu May 19, 2:24AM CDT
Merck KGaA (MKGAF) first-quarter 2016 earnings per American Depositary Receipt (ADR) came in at $1.5.
Merck KGaA (MKGAF) Q1 Earnings: What Awaits the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:38AM CDT
Merck KGaA (MKGAF) is scheduled to report its first-quarter 2016 earnings results on May 19.
AXON: 16.69 (+0.61), BMRN: 96.22 (+1.25), PFE: 34.82 (+0.05)
Intrexon (XON) Q1 Loss Wider than Expected, Revenues Miss
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:30AM CDT
Intrexon Corporation (XON) reported a wider-than-expected first-quarter 2016 loss of 32 cents per share.
FCSC: 0.87 (-0.02), ANIP: 63.17 (+0.30), XON: 26.12 (+0.44)
Pfizer & Merck KGaA Partner with Syndax for Ovarian Cancer
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 12:50PM CST
Pfizer (PFE) and Merck KGaA (MKGAF) teamed up with Syndax Pharmaceuticals to evaluate the avelumab/entinostat combination for ovarian cancer.
PFE: 34.82 (+0.05), HZNP: 19.43 (+0.25), ARNA: 1.63 (unch)
Pfizer/Merck KGaA Start Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 3:30PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of ovarian cancer and urothelial cancer.
ACHN: 8.54 (-0.06), PFE: 34.82 (+0.05), ANIK: 48.36 (-0.36)
Pfizer/Merck KGaA Begin Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Thu Dec 10, 2:20PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of advanced or metastatic gastric/gastro-esophageal junction cancers.
ACHN: 8.54 (-0.06), PFE: 34.82 (+0.05), ANIK: 48.36 (-0.36)
Merck KGaA-Pfizer's Avelumab May Get Orphan Status in EU
Zacks Equity Research - Zacks Investment Research - Fri Nov 27, 1:40PM CST
Merck KGaA (MKGAF) and Pfizer (PFE) announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for immunotherapy candidate, avelumab.
MRK: 62.85 (+0.53), PFE: 34.82 (+0.05), CORT: 5.50 (+0.05)
Pfizer's (PFE) Xalkori Positive in Another Phase III Study
Arpita Dutt - Zacks Investment Research - Thu Nov 19, 1:52PM CST
Pfizer's (PFE) Xalkori scored in another phase III study. The company also got breakthrough therapy status for avelumab.
AGN: 237.93 (+1.62), PFE: 34.82 (+0.05), LLY: 78.24 (+0.23)
Intrexon (XON) Reports Wider-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Tue Nov 10, 9:30AM CST
Intrexon Corporation (XON) reported third-quarter 2015 loss of 34 cents per share.
XON: 26.12 (+0.44), BXLT: 46.02 (-0.18), ANIK: 48.36 (-0.36)
Merck KGaA/Pfizer's Avelumab Gets Fast Track Status
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:50PM CDT
Merck KGaA (MKGAF) and Pfizer announced that avelumab received fast track status from the FDA for metastatic merkel cell carcinoma.
MRK: 62.85 (+0.53), PFE: 34.82 (+0.05), CORT: 5.50 (+0.05)
Merck KGaA's Pipeline on Track, Updates Key R&D Projects
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:40PM CDT
Merck KGaA (MKGAF) provided an update regarding the stages of development of its key immuno-oncology and oncology pipeline candidates.
ENDP: 21.03 (unch), PFE: 34.82 (+0.05), CORT: 5.50 (+0.05)
BioMarin (BMRN) to Acquire Rights to Phenylketonuria Drugs
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:10PM CDT
BioMarin (BMRN) announced that it has acquired all global rights to Kuvan and pegvaliase from Merck Serono, a division of Merck KGaA (MKGAF).
BMRN: 96.22 (+1.25), NVET: 4.22 (-0.11), REGN: 402.97 (+2.72)
Roche's Primary Progressive MS Drug Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Mon Sep 28, 3:20PM CDT
Roche (RHHBY) announced encouraging results from the phase III ORATORIO study on ocrelizumab for primary progressive multiple sclerosis.
PFE: 34.82 (+0.05), LLY: 78.24 (+0.23), NVS: 79.31 (-0.24)
